Altimmune leveraging novel intranasal technology in the race against coronavirus
Altimmune Inc (NASDAQ: ALT), a clinical stage biotechnology Company developing immunotherapies for unmet medical needs, announced that the Company has completed designing and synthesis of a novel single-dose, intranasal vaccine to protect against COVID-19, developed using its proprietary intranasal vaccine technology. [caption id="attachment_20787" align="aligncenter" width="271"] Image...
